Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study

Rheumatoid arthritis (RA) is the most common inflammatory joint disorder. Since twenty year and the use of synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and biological (b)DMARD, remission can be reached. When remission is obtained, the physician has no recommendations for managing a step-down, and future guidelines will be useful to assist the clinician. Recent data suggest that tapering is feasible, but with high risk of flares. Flares are less frequent when bDMARD blood concentration is high. But, the optimal adalimumab concentration to keep before a step of tapering no targeting personal is unknown.

NCT Number	NCT06528431
Lead Sponsor	Centre Hospitalier Universitaire de Saint Etienne Collaborators: AAP MESSIDOR
Conditions	Arthritis, Rheumatoid
Enrollment	180 participants
Start Date	2024-12-19
Primary Completion	2026-09-19 (estimated)
Study Completion	2027-12-19 (estimated)
Updated on ClinicalTrials.gov	2025-12-26